Address: Gillooly’s View Office Park
Block A
5 Osborne Lane
Bedfordview
Johannesburg
South Africa
,South Africa
Tel: +27(011) 615 9433
Web: http://www.astellas.eu/contact/locations/sa/
Astellas Pharma Ltd., was established as Yamanouchi Pharma in South Africa in June 2003. Prior to this, Yamanouchi operated as an agency for five years under the umbrella of Pharmaplan.
In South Africa, Astellas employs 27 people in 2011, of whom 16 are sales representatives. The company has established itself as a leading player in the therapy fields of Transplantation, Urology, and Dermatology.
In order to realise Astellas’ business philosophy to contribute towards improving the health of people around the world through the provision of innovative and reliable pharmaceutical products, VISION 2015 has been developed to represent Astellas’ goals and aspirations for the future.
With VISION 2015, Astellas aims to become a Global Category Leader (GCL) in several therapeutic areas in which high unmet medical needs exist and a high degree of expertise is required. Astellas seeks to provide value-added healthcare products globally and enhance its enterprise value in a sustainable manner.
Recognising the emerging complexity and segmentation of the pharmaceutical marketplace, the Astellas global business model works to evolve and expand the company as a GCL in a variety of markets.
With insight and determination, Astellas will move to achieve GCL status by concentrating on six product categories of unmet medical needs, market potential, and research potential: Urology, Inflammation/Immunology, Infectious Diseases (including viruses), Neurology/Pain, Diabetes, and Oncology.
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
The managing director at Adcock Ingram Critical Care reveals the company’s unique business model. As a long-established division within Adcock Ingram, Critical Care operates with relative independence. What is the relationship…
The head of operations of Hetero South Africa talks about the need for a more efficient regulatory system with a fast track process for essential molecules, and how Hetero is…
The CEO of Ascendis Health talks about their business model, being a long-term investment company that brings together healthy businesses in the healthcare industry, and how the diversification of their product…
Merck’s managing director for South Africa and general manager for Southeast Africa reveals why the company takes a long-term perspective when investing in African countries, helping to shape healthcare systems,…
The general manager of Novagen Pharma reveals how they are the second largest supplier of ARVs within the private South African market, how there is much room for the generics…
The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is…
The country manager of Dr. Reddy´s South Africa explains that while the perception of the quality of generics has improved in South Africa, there is still a long way to…
The CEO of NAPM reveals how the main challenge facing his members is the length of time needed to register a generic product, taking up to four years and acting…
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
Our international readers know about South Africa’s socio-economic relative achievements, considering the country joined the BRICS grouping last year and achieved the first Millennium Development Goal (MDG) that same year.…
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
The story of Novo Nordisk South Africa began in 1959 in Johannesburg. It was among the first affiliates outside of Denmark, with insulin and anti-infectives produced locally. To what extent…
See our Cookie Privacy Policy Here
